Acute encephalitis syndrome (AES) is characterized by an acute onset of fever and clinical neurological manifestation that includes mental confusion, disorientation, delirium, or coma [1] . Viruses have been mainly attributed to be the cause of AES in India although other sources such as bacteria, fungus, parasites, spirochetes, chemical, and toxins have been reported over the past few decades [1] . Apart from viral encephalitis, severe form of leptospirosis and toxoplasmosis can cause AES. The causative agent of AES varies with season and geographical location, and predominantly affects population below 15 years [1] . Keeping in mind the wide range of causal agents and the rapid rate of neurological impairment due to pathogenesis, clinicians face the challenge of a small window period between diagnosis and treatment. The present report is based on results obtained after reviewing various surveillance and outbreak investigations illustrating how the perspective of AES has changed in India over the years.
The history of AES in India has paralleled with that of the Japanese encephalitis virus (JEV) since the first report in 1955 from Vellore, Tamil Nadu. The first outbreak of JEV was reported in Bankura district, West Bengal in 1973. Thereafter, sporadic cases of AES and outbreaks have been the leading cause of premature deaths due to the disease in India. Based on various surveillance reports and outbreak investigations, Joshi et al. [1] classified the history of AES in India into 3 phases: (a) period before 1975 when a few cases with JE aetiology were identified; treatment for hypoglycaemia reduced the number of deaths from 44% in 2013 to 26% in 2014. The toxin was identified as methylene cyclopropyl glycine and was found to rise in litchi seed. Later, though not confirmed, the rise in the toxin in litchi seeds was implied to the use of alpha cypermethrin above the minimum safety levels (Indian Express, July 23, 2014).
Several government initiatives have been undertaken to educate and improve the hygiene of people living in the JE endemic zones. Government and non-government organizations have been instrumental in providing proper nutrition to the AES-affected population as most of the affected people belong to the lower economic strata of the society. There have been initiatives to help the people residing in the endemic zones for alternative professions such as giving up pig-rearing since pigs are the primary host for JE viruses. Special schools have been set up to help children challenged by clinical sequelae of JE infection (Indian Express, October 19, 2012). Vero cell-derived purified inactivated JE vaccine-JENVAC, was the first vaccine in India that received manufacturing and marketing approvals from the Drug Controller General of India. The vaccine was an outcome of public-private partnership mode between the Indian Council of Medical Research and Bharat Biotech (The Hindu, October 4, 2013). Minocycline, a second generation tetracycline was reported from our laboratory to be protective against JE in the animal model [2] . Based on a pre-clinical study, a phase II clinical trial has been completed at the CSM Medical University (King George Medical College). The trial report showed better outcomes with minocycline, especially in those patients who survived the initial day in hospital [3] , although the exact mechanism of action has remained enigmatic.
AES was coined way back in 2008 by the World Health Organization to streamline the surveillance and research of AES in India. Over the years, the scenario of AES in India has improved significantly in terms of research and health care facilities. Albeit the development of vaccine against JEV and minocycline under the clinical trials, AES cases in India has not restricted itself to the JE aetiology. This is the biggest challenge clinicians in the field are facing. As mentioned previously, viruses such as CHPV, NiV often emerge in the scenario, leading to massive outbreaks. Development of pan-anti-viral drugs is the order of the day. Pan-anti-viral drugs are not only effective across a wide range of viruses, but they also reduce the time lost between the identification of the virus and treatment.
